This presentation looks at ways in which governments can set prices, including “cost plus”, value, and the external referencing of prices elsewhere. It looks at the role that competition can play in keeping down prices. In that context it briefly discusses pricing proposals being considered in Malaysia. It makes the case for using HTA to inform pricing decisions.
Adrian Towse
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
This presentation looks at rates of GDP spend on health care, distinguishing between categories of country (i.e. levels of GDP pre capita). It looks at the relationship between rates of spending and moves to universal health coverage, and explores alternative ways of increasing expenditure and making decisions about which services to provide with the money available.
Overview presentation on Environmental Product Declarations (EPDs) delivered by Dr. John Harvey of the University of California Pavement Research Center (UCPRC) at the CalAPA EPD workshop on Oct. 25, 2023 in Sacramento.
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
Rising Importance of Health Economics & Outcomes ResearchCitiusTech
Health Economics & Outcomes Research (HE&OR) guides stakeholders to make informed decisions regarding patient access to drugs and services. This document highlights specific use cases for healthcare information technology that add value to HE&OR.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
This presentation looks at rates of GDP spend on health care, distinguishing between categories of country (i.e. levels of GDP pre capita). It looks at the relationship between rates of spending and moves to universal health coverage, and explores alternative ways of increasing expenditure and making decisions about which services to provide with the money available.
Overview presentation on Environmental Product Declarations (EPDs) delivered by Dr. John Harvey of the University of California Pavement Research Center (UCPRC) at the CalAPA EPD workshop on Oct. 25, 2023 in Sacramento.
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
Rising Importance of Health Economics & Outcomes ResearchCitiusTech
Health Economics & Outcomes Research (HE&OR) guides stakeholders to make informed decisions regarding patient access to drugs and services. This document highlights specific use cases for healthcare information technology that add value to HE&OR.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
"Unmet need" generally indicates that a particular disease cannot be adequately treated, or perhaps treated at all. In this presentation, Koonal Shah notes the definitions and the approaches to measuring "need" that have appeared in the literature. A recent exploratory empirical study also is reviewed. This research focused on the extent to which member of the general public believe that "unmet need" should be ranked high in priority in decisions that allocate health care resources.
This describes the background problem, concept of health insurance, enrollment procedure, benefits,and implementation status of health insurance in Nepal, issues/concerns (discussion), take home message
> Why HEOR?
> Costs, Consequences and Perspectives
> Key Stakeholders in HEOR
> What is Health Economics and Pharmaco-economic Research?
> Economic Evaluations
> Incremental Cost Effectiveness Ratio (ICER)
> Concept of HRQoL
> Comparative Effectiveness Research (CER)
> Pragmatic Clinical Trials
> Observational Studies
> Systematic Reviews and Meta-Analysis
> Application of CER
> Health Technology Assessment (HTA)
> Real World Evidence (RWE)
> Patient Reported Outcomes (PROs)
> Patient Focused Drug Development (PFDD)
> Application of Health Economic Evaluations
> Challenges and Barriers
Researcher KnowHow session presented by Ruaraidh Hill PhD MSc FHEA Lecturer in evidence synthesis at the University of Liverpool and Angela Boland MSc PhD PGCert (LTHE)Director –Liverpool Reviews & Implementation Group
A simple explanation of Exploratory Factor Analysis: For some learners, it is hard to apprehend the concept of factory analysis. This presentation will clarify all the doubts. Also, there is SAS program code of the example explained in the slides.
Created by the Climate Disclosure Standards Board (CDSB) and the Sustainability Accounting Standards Board (SASB), the TCFD Good Practice Handbook offers real-world examples of TCFD aligned disclosures in mainstream reports across many G20 countries. Striking a balance between financial and non-financial sectors, the Handbook helps you understand how organisations in your industry are implementing the TCFD recommendations and provide insight into good practice techniques to enhance your own climate-related financial disclosures.
"Unmet need" generally indicates that a particular disease cannot be adequately treated, or perhaps treated at all. In this presentation, Koonal Shah notes the definitions and the approaches to measuring "need" that have appeared in the literature. A recent exploratory empirical study also is reviewed. This research focused on the extent to which member of the general public believe that "unmet need" should be ranked high in priority in decisions that allocate health care resources.
This describes the background problem, concept of health insurance, enrollment procedure, benefits,and implementation status of health insurance in Nepal, issues/concerns (discussion), take home message
> Why HEOR?
> Costs, Consequences and Perspectives
> Key Stakeholders in HEOR
> What is Health Economics and Pharmaco-economic Research?
> Economic Evaluations
> Incremental Cost Effectiveness Ratio (ICER)
> Concept of HRQoL
> Comparative Effectiveness Research (CER)
> Pragmatic Clinical Trials
> Observational Studies
> Systematic Reviews and Meta-Analysis
> Application of CER
> Health Technology Assessment (HTA)
> Real World Evidence (RWE)
> Patient Reported Outcomes (PROs)
> Patient Focused Drug Development (PFDD)
> Application of Health Economic Evaluations
> Challenges and Barriers
Researcher KnowHow session presented by Ruaraidh Hill PhD MSc FHEA Lecturer in evidence synthesis at the University of Liverpool and Angela Boland MSc PhD PGCert (LTHE)Director –Liverpool Reviews & Implementation Group
A simple explanation of Exploratory Factor Analysis: For some learners, it is hard to apprehend the concept of factory analysis. This presentation will clarify all the doubts. Also, there is SAS program code of the example explained in the slides.
Created by the Climate Disclosure Standards Board (CDSB) and the Sustainability Accounting Standards Board (SASB), the TCFD Good Practice Handbook offers real-world examples of TCFD aligned disclosures in mainstream reports across many G20 countries. Striking a balance between financial and non-financial sectors, the Handbook helps you understand how organisations in your industry are implementing the TCFD recommendations and provide insight into good practice techniques to enhance your own climate-related financial disclosures.
Achieving efficient pricing of pharmaceuticals between and within countries is a complex conceptually and critical a policy challenge. The optimal price that maximises social welfare must achieve two objectives: static efficiency, i.e. optimal use of existing products, and dynamic efficiency, i.e. optimal investment in R&D. This presentation reviews recent thinking on the core challenges.
Beyond-the-pill: how to move from selling pills to value-added solutionsexecutiveinsight
New shores: The shift from selling pills to developing value-added services has only just begun!
Biopharma companies are discovering that compelling and aligned services underpinned by a core strategy are providing them with distinctive competitive advantages.
Government cost containment methods in Asia-Pacific markets are as diverse as the cultures represented in the region, so what lessons are the markets leveraging from cost containment experiences? And what, in the end, are pharmaceutical companies supposed to do about it?
Reimbursement and pricing strategies for drugs for ultra rare diseases: What can Canada learn from experiences across the pond?
Tania Stafinski, University of Alberta
Rare Disease Day Conference 2020 March 9-10
Global pricing and launching of new drugs. An econometric approachPydesalud
Comunicación oral de Borja García (técnico del SESCS) en torno al análisis econométrico sobre la fijación de precios y lanzamiento de nuevos fármacos a nivel internacional. Fue presentada en la XXXIV edición de las Jornadas de Economía de la Salud organizadas por la Asociación de Economía de la Salud (AES). Pamplona, 27-30 mayo de 2014.
Similar to Pricing in emerging markets: options to get value for money - Adrian Towse (20)
On 31 October 2019, Adrian Towse and Chris Henshall from the Office of Health Economics (OHE) presented at the G20 meeting on antimicrobial drugs R&D in Paris organised by the Wellcome Trust. The topic of their presentation was HTA and payment mechanisms for new drugs to tackle antimicrobial resistance.
The aim of this educational symposium was to discuss why we should seek value across the health care system and how we can apply existing research methods to measure the value of services. While considerable political attention in developed countries continues to be focused on drug spending, there is also growing awareness of the significant contribution of non-drug components of health care (e.g., hospital services and inefficient care delivery) to overall spending growth and patient affordability. At the same time, there is growing interest in making greater use of value assessment and value-based payment to control spending and better align it with care quality. In order to promote greater value, and to do so in ways that respond to the needs of payers and patients, it is essential to assess value across both drug- and non-drug interventions and health care services. This panel will offer expert viewpoints to identify and discuss gaps in value information, rationale and approaches to track and reduce system-wide low value care, and research methods for how to measure health care services.
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
Graham participated in an organised session on Monday July 15th 2019. In the session he presented his paper with his co-author Ioannis Laliotis from the London School of Economics. The paper revisits the relationship between workforce and maternity outcomes in the English NHS in an attempt to contribute knowledge to an important policy question for which there has been a paucity of research.
This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and
which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare
professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
Poster presentation from the EuroQol Plenary Meeting 2019, Brussels, Belgium. By Koonal Shah, Brendan Mulhern, Patricia Cubi-Molla, Bas Janssen, and David Mott.
Koonal presented as part of an organised session on ‘moving beyond conventional economic approaches in palliative and end of life care’. He summarised the empirical evidence on the extent of pubic support for an end of life premium, before discussing some novel approaches that have been used in recent studies. His presentation was discussed by Helen Mason of Glasgow Caledonian University.
Author(s) and affiliation(s): Koonal Shah, Office of Health Economics
Event: iHEA Congress
Date: 17/07/2019
Location: Basel, Switzerland
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and a number of recommendations for adapting these systems to respond to the challenges of AMR.
Author(s) and affiliation(s): Margherita Neri (OHE) Grace Hampson (OHE) Christopher Henshall (OHE visiting fellow, independent consultant) Adrian Towse (OHE)
Event: HTAi annual conference 2019
Date: 18/06/2019
Location: Cologne, Germany
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
This study aims to guide access decisions and drive the discussion on access and price, through recognition of the dynamic nature of value added by pharmaceutical innovation over the long-run. The analysis of the life-cycle value of risperidone estimates the value generated in the UK and Sweden. Results show that health systems were able to appropriate most of the life-cycle value generated, and this is larger than estimated at launch.
Author(s) and affiliation(s): Mikel Berdud(1), Niklas Wallin-Bernhardsson(2), Bernarda Zamora(1), Peter Lindgren(2), and Adrian Towse(1) (1) Office of Health Economics (2) The Swedish Institute for. Health Economics
Event: XXXIX JORNADAS DE ECONOMÍA DE LA SALUD
Date: 12/06/2019
Location: Albacete, Spain
Prescribed Specialised Services (PSS) Commissioning for Quality and Innovation (CQUIN) schemes were launched in 2013 in England with the aim of improving the quality of specialised care and achieving value for money. During this presentation, Marina Rodes Sanchez described the key features of the schemes and discussed its strengths and weaknesses based on international pay-for-performance literature.
Author(s) and affiliation(s): Yan Feng, Queen Mary University of London; Søren Rud Kristensen, Imperial College London; Paula Lorgelly, King’s College London; Rachel Meacock, University of Manchester; Marina Rodes Sanchez, Office of Health Economics; Luigi Siciliani, University of York; Matt Sutton, University of Manchester
Event: XXXIX Spanish Health Economics Association Conference
Date: 12/06/2019
Location: Albacete, Spain
In this session, Meng Li sets out estimates of real option value for drugs arguing that option value matters and can be calculated. Adrian Towse sets out likely payer concerns about incorporating real option value into decision making. Meng Li responds to these concerns. Jens Grueger sets out how industry considers investment opportunities, arguing that if patients (and society) have preferences these need to be reflected in P&R decisions.
Author(s) and affiliation(s): Meng Li, Postdoctoral Research Fellow, Leonard D Schaeffer Center, University of Southern California, Los Angeles, CA, USA. Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Jens Grueger, formerly Head of Global Access, Senior Vice President at F. Hoffmann-La Roche
Event: ISPOR 2019
Location: New Orleans, USA
Date: 21/05/2019
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
In this ISPOR session Chuck Phelps and Adrian Towse debated the case for and against using MCDA to support HTA decision making, as compared to weighting or augmenting a QALY based ICER approach. Chuck Phelps argued for use of MCDA, Adrian Towse for weighting the QALY. Nancy Devlin set the scene and moderated.
Author(s) and affiliation(s): Nancy Devlin, Director, Centre for Health Policy, University of Melbourne, Australia Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Chuck Phelps, University of Rochester, Rochester, NY USA
Event: ISPOR 2019
Location: New Orleans, USA
Date: 21/05/2019
The issue of open-source models in the cost-effectiveness and disease-level (collaborative) models has been brewing for many years. There has been a marked growth in open science, and funding bodies and publishers increasingly require that research data be made available. As mentioned in our previous Issue Panel, “cost-effectiveness models synthesise a wide range of evidence to facilitate extrapolation over time and from intermediate to final decision endpoints. These models are often statistically sophisticated and require assumptions that are not directly testable. This can lead to decision-makers “discounting” the results of cost-effectiveness analyses, particularly if the developer is seen as partial.” Open-source models, then, would encourage greater transparency in pharmacoeconomic modeling and the reuse and updating of the best/most useful models; they are essential if cost-effectiveness analyses are to be widely accepted to reduce bias, increase transparency, improve model access, and allow for faster access to critical knowledge. The ISPOR-SMDM guidelines and the EUnetHTA joint action projects, are supportive of these views on collaboration, transparency, confidentiality, processes and consistency offered by the availability of open-source models to improve decision-making around health care and reimbursement. With openness and sharing, however, come issues of copyright and access and a need to define how model sharing can be achieved in a fair and equitable manner. There is, therefore, a need to develop an ongoing dialog on openness, especially where the research may be considered precompetitive and not worthy of IP investment. The pros and cons of open source models and the proposed mission of the Open Source Model SIG to curate an ongoing dialog regarding issues around creating, disseminating, sharing, evaluating, and updating open source cost-effectiveness and comparative effectiveness models will be debated amongst SIG members.
Author(s) and affiliation(s): Nancy Risebrough, Senior Principal, ICON plc, Toronto, Canada Jeroen P Jansen; Innovation & Value Initiative; Precision Medicine Group; and Stanford University Lotte Steuten, Vice President & Head of Consulting, Office of Health Economics, UK Renée JG Arnold, PharmD, RPh, ICON plc, New York, NY and Icahn School of Medicine at Mount Sinai, New York, NY, USA
Event: ISPOR 2019 Annual Meeting
Date: 20/05/2019
NGS-based diagnostic testing compared to single-marker genetic testing (SMGT), has the potential to improve testing efficiency and to identify more cancer patients who could benefit from targeted therapies, but the impact on outcomes and total costs of care is uncertain. Recent studies using simulation modeling informed with data from the Flatiron Health database, representing curated electronic health record-derived clinical information from 191 oncology practices, has shown only moderate cost effectiveness of NGS vs. SGMT for patients with advanced non-small cell lung cancer (aNSCLC). The data suggests, however, that efforts to increase the proportion of patients who receive targeted therapies would improve the cost-effectiveness of NGS. To effectively inform access and reimbursement policy decisions there is a need to examine the NGS value proposition from the perspective of all stakeholders.
Author(s) and affiliation(s): Lotte Steuten (Office of Health Economics, London, UK); Bernardo Goulart (Fred Hutchinson Cancer Research Center, Seattle, WA, US & Seattle Cancer Care Alliance, Seattle, WA, US); Neal J. Meropol (Flatiron Health, New York, NY, US & Case Western Reserve University, Cleveland, OH, US); Daryl Pritchard (Personalized Medicine Coalition, Washington, DC, US); and Scott D. Ramsey (Fred Hutchinson Cancer Research Center, Seattle, WA, US)
Event: ISPOR 2019
Location: New Orleans, LA, United States
Date: 20/05/2019
Graham was invited to the weekly seminar series by the Royal Brompton Hospital to deliver a presentation on health economics pertinent to Respiratory medicine. They care for a large number of patients with complex lung diseases at the institution and juggle the varied issues of resource (human, structural or financial). As one of many examples, high cost drugs for treating relatively unusual conditions comes up for debate all too frequently. The audience included consultant physicians, senior and junior trainees, nurses and other allied health professionals.
Date: 7 March 2019
Location: The Royal Brompton, London, UK
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...beulahfernandes8
The financial landscape in India has witnessed a significant development with the recent collaboration between Poonawalla Fincorp and IndusInd Bank.
The launch of the co-branded credit card, the IndusInd Bank Poonawalla Fincorp eLITE RuPay Platinum Credit Card, marks a major milestone for both entities.
This strategic move aims to redefine and elevate the banking experience for customers.
how to sell pi coins on Bitmart crypto exchangeDOT TECH
Yes. Pi network coins can be exchanged but not on bitmart exchange. Because pi network is still in the enclosed mainnet. The only way pioneers are able to trade pi coins is by reselling the pi coins to pi verified merchants.
A verified merchant is someone who buys pi network coins and resell it to exchanges looking forward to hold till mainnet launch.
I will leave the telegram contact of my personal pi merchant to trade with.
@Pi_vendor_247
US Economic Outlook - Being Decided - M Capital Group August 2021.pdfpchutichetpong
The U.S. economy is continuing its impressive recovery from the COVID-19 pandemic and not slowing down despite re-occurring bumps. The U.S. savings rate reached its highest ever recorded level at 34% in April 2020 and Americans seem ready to spend. The sectors that had been hurt the most by the pandemic specifically reduced consumer spending, like retail, leisure, hospitality, and travel, are now experiencing massive growth in revenue and job openings.
Could this growth lead to a “Roaring Twenties”? As quickly as the U.S. economy contracted, experiencing a 9.1% drop in economic output relative to the business cycle in Q2 2020, the largest in recorded history, it has rebounded beyond expectations. This surprising growth seems to be fueled by the U.S. government’s aggressive fiscal and monetary policies, and an increase in consumer spending as mobility restrictions are lifted. Unemployment rates between June 2020 and June 2021 decreased by 5.2%, while the demand for labor is increasing, coupled with increasing wages to incentivize Americans to rejoin the labor force. Schools and businesses are expected to fully reopen soon. In parallel, vaccination rates across the country and the world continue to rise, with full vaccination rates of 50% and 14.8% respectively.
However, it is not completely smooth sailing from here. According to M Capital Group, the main risks that threaten the continued growth of the U.S. economy are inflation, unsettled trade relations, and another wave of Covid-19 mutations that could shut down the world again. Have we learned from the past year of COVID-19 and adapted our economy accordingly?
“In order for the U.S. economy to continue growing, whether there is another wave or not, the U.S. needs to focus on diversifying supply chains, supporting business investment, and maintaining consumer spending,” says Grace Feeley, a research analyst at M Capital Group.
While the economic indicators are positive, the risks are coming closer to manifesting and threatening such growth. The new variants spreading throughout the world, Delta, Lambda, and Gamma, are vaccine-resistant and muddy the predictions made about the economy and health of the country. These variants bring back the feeling of uncertainty that has wreaked havoc not only on the stock market but the mindset of people around the world. MCG provides unique insight on how to mitigate these risks to possibly ensure a bright economic future.
Financial Assets: Debit vs Equity Securities.pptxWrito-Finance
financial assets represent claim for future benefit or cash. Financial assets are formed by establishing contracts between participants. These financial assets are used for collection of huge amounts of money for business purposes.
Two major Types: Debt Securities and Equity Securities.
Debt Securities are Also known as fixed-income securities or instruments. The type of assets is formed by establishing contracts between investor and issuer of the asset.
• The first type of Debit securities is BONDS. Bonds are issued by corporations and government (both local and national government).
• The second important type of Debit security is NOTES. Apart from similarities associated with notes and bonds, notes have shorter term maturity.
• The 3rd important type of Debit security is TRESURY BILLS. These securities have short-term ranging from three months, six months, and one year. Issuer of such securities are governments.
• Above discussed debit securities are mostly issued by governments and corporations. CERTIFICATE OF DEPOSITS CDs are issued by Banks and Financial Institutions. Risk factor associated with CDs gets reduced when issued by reputable institutions or Banks.
Following are the risk attached with debt securities: Credit risk, interest rate risk and currency risk
There are no fixed maturity dates in such securities, and asset’s value is determined by company’s performance. There are two major types of equity securities: common stock and preferred stock.
Common Stock: These are simple equity securities and bear no complexities which the preferred stock bears. Holders of such securities or instrument have the voting rights when it comes to select the company’s board of director or the business decisions to be made.
Preferred Stock: Preferred stocks are sometime referred to as hybrid securities, because it contains elements of both debit security and equity security. Preferred stock confers ownership rights to security holder that is why it is equity instrument
<a href="https://www.writofinance.com/equity-securities-features-types-risk/" >Equity securities </a> as a whole is used for capital funding for companies. Companies have multiple expenses to cover. Potential growth of company is required in competitive market. So, these securities are used for capital generation, and then uses it for company’s growth.
Concluding remarks
Both are employed in business. Businesses are often established through debit securities, then what is the need for equity securities. Companies have to cover multiple expenses and expansion of business. They can also use equity instruments for repayment of debits. So, there are multiple uses for securities. As an investor, you need tools for analysis. Investment decisions are made by carefully analyzing the market. For better analysis of the stock market, investors often employ financial analysis of companies.
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...Vighnesh Shashtri
In India, financial inclusion remains a critical challenge, with a significant portion of the population still unbanked. Non-Banking Financial Companies (NBFCs) have emerged as key players in bridging this gap by providing financial services to those often overlooked by traditional banking institutions. This article delves into how NBFCs are fostering financial inclusion and empowering the unbanked.
Even tho Pi network is not listed on any exchange yet.
Buying/Selling or investing in pi network coins is highly possible through the help of vendors. You can buy from vendors[ buy directly from the pi network miners and resell it]. I will leave the telegram contact of my personal vendor.
@Pi_vendor_247
USDA Loans in California: A Comprehensive Overview.pptxmarketing367770
USDA Loans in California: A Comprehensive Overview
If you're dreaming of owning a home in California's rural or suburban areas, a USDA loan might be the perfect solution. The U.S. Department of Agriculture (USDA) offers these loans to help low-to-moderate-income individuals and families achieve homeownership.
Key Features of USDA Loans:
Zero Down Payment: USDA loans require no down payment, making homeownership more accessible.
Competitive Interest Rates: These loans often come with lower interest rates compared to conventional loans.
Flexible Credit Requirements: USDA loans have more lenient credit score requirements, helping those with less-than-perfect credit.
Guaranteed Loan Program: The USDA guarantees a portion of the loan, reducing risk for lenders and expanding borrowing options.
Eligibility Criteria:
Location: The property must be located in a USDA-designated rural or suburban area. Many areas in California qualify.
Income Limits: Applicants must meet income guidelines, which vary by region and household size.
Primary Residence: The home must be used as the borrower's primary residence.
Application Process:
Find a USDA-Approved Lender: Not all lenders offer USDA loans, so it's essential to choose one approved by the USDA.
Pre-Qualification: Determine your eligibility and the amount you can borrow.
Property Search: Look for properties in eligible rural or suburban areas.
Loan Application: Submit your application, including financial and personal information.
Processing and Approval: The lender and USDA will review your application. If approved, you can proceed to closing.
USDA loans are an excellent option for those looking to buy a home in California's rural and suburban areas. With no down payment and flexible requirements, these loans make homeownership more attainable for many families. Explore your eligibility today and take the first step toward owning your dream home.
how can i use my minded pi coins I need some funds.DOT TECH
If you are interested in selling your pi coins, i have a verified pi merchant, who buys pi coins and resell them to exchanges looking forward to hold till mainnet launch.
Because the core team has announced that pi network will not be doing any pre-sale. The only way exchanges like huobi, bitmart and hotbit can get pi is by buying from miners.
Now a merchant stands in between these exchanges and the miners. As a link to make transactions smooth. Because right now in the enclosed mainnet you can't sell pi coins your self. You need the help of a merchant,
i will leave the telegram contact of my personal pi merchant below. 👇 I and my friends has traded more than 3000pi coins with him successfully.
@Pi_vendor_247
where can I find a legit pi merchant onlineDOT TECH
Yes. This is very easy what you need is a recommendation from someone who has successfully traded pi coins before with a merchant.
Who is a pi merchant?
A pi merchant is someone who buys pi network coins and resell them to Investors looking forward to hold thousands of pi coins before the open mainnet.
I will leave the telegram contact of my personal pi merchant to trade with
@Pi_vendor_247
how to sell pi coins in South Korea profitably.DOT TECH
Yes. You can sell your pi network coins in South Korea or any other country, by finding a verified pi merchant
What is a verified pi merchant?
Since pi network is not launched yet on any exchange, the only way you can sell pi coins is by selling to a verified pi merchant, and this is because pi network is not launched yet on any exchange and no pre-sale or ico offerings Is done on pi.
Since there is no pre-sale, the only way exchanges can get pi is by buying from miners. So a pi merchant facilitates these transactions by acting as a bridge for both transactions.
How can i find a pi vendor/merchant?
Well for those who haven't traded with a pi merchant or who don't already have one. I will leave the telegram id of my personal pi merchant who i trade pi with.
Tele gram: @Pi_vendor_247
#pi #sell #nigeria #pinetwork #picoins #sellpi #Nigerian #tradepi #pinetworkcoins #sellmypi
How to get verified on Coinbase Account?_.docxBuy bitget
t's important to note that buying verified Coinbase accounts is not recommended and may violate Coinbase's terms of service. Instead of searching to "buy verified Coinbase accounts," follow the proper steps to verify your own account to ensure compliance and security.
how to sell pi coins in all Africa Countries.DOT TECH
Yes. You can sell your pi network for other cryptocurrencies like Bitcoin, usdt , Ethereum and other currencies And this is done easily with the help from a pi merchant.
What is a pi merchant ?
Since pi is not launched yet in any exchange. The only way you can sell right now is through merchants.
A verified Pi merchant is someone who buys pi network coins from miners and resell them to investors looking forward to hold massive quantities of pi coins before mainnet launch in 2026.
I will leave the telegram contact of my personal pi merchant to trade with.
@Pi_vendor_247
Pricing in emerging markets: options to get value for money - Adrian Towse
1. #OHEMasterclass
Adrian Towse
Emeritus Director OHE Visiting
Professor LSE
Pricing in emerging markets:
options to get value for money
Monash Health Economics Forum 2019
An efficient and sustainable healthcare system
in Malaysia :
The challenges, lessons and future
2. Agenda
●Rationale for intervention over pharmaceutical prices
●Differential pricing
●OOP and off-patent markets
●Five types of price control
●Pricing proposals in Malaysia
●The challenges of reference pricing
●A way forward – the case for HTA and VBDP
●Conclusions
3. Rationale for intervention over pharmaceutical price
●Countries have universal health coverage with low patient copayments, or
are seeking to move in this direction.
●By lowering out-of-pocket prices to patients, insurance counteracts the
financial impact on patients of companies using patent protection to charge
high prices
●It protects patients from financial risk and, through cross subsidies, makes
health services affordable
●However, health insurance makes patient demand highly price-inelastic
●It creates incentives for manufacturers to charge prices that exceed the
level that would result from patents alone.
●Public and private insurers use various forms of price regulatory strategies
to constrain this producer moral hazard.
4. Differential pricing
● It is important to note that the point of patent protection is to give market power to the owner, subject
to competition within the therapy area
● R&D costs and sunk and global. They need to be recovered in an efficient way from different markets
● It is efficient if R&D costs are recovered in relation to the value of the health and health related benefit
delivered. This will be impacted by:
● Size of the benefit
● The willingness to pay for that benefit. This will be budget constrained
● This means prices will vary depending on factors including income-per-capita, i.e. the budget
constraints health systems face. We will see differential pricing.
● In countries with pluralistic health systems (e.g. the USA) we will see different prices within countries
● Differential pricing will happen less if we see:
● Price referencing or the arbitrage (physical movement) of goods
5. Out-of-pocket and off-patent markets
●Note that this rationale would not apply to:
●Out-of-pocket (OOP) purchases where there was no insurance
●Off-patent markets with potential competition to supply the same molecule
●We often see price controls in both of these markets
●The rationale for intervening in OOP markets would be that there is a lack of patient buying
power. But is that the case and if so are there other remedies?
- Some governments use price control on drugs purchased OOP or as part of hospital care purchased OOP as a
substitute for providing health coverage. This is not efficient.
●In off-patent markets it is more efficient to encourage competition. Price control inhibits
competition
- It is also essential to have high quality regulation of off-patent medicine producers. Otherwise patients paying
OOP do not have a guarantee of quality
6. Types of price control: five broad types (1)
●Cost-effectiveness requirements
●Drugs are assessed for use or for a reimbursement price by looking at incremental health-related effects (often
measured and valued using the quality-adjusted life-year (QALY) and incremental costs relative to existing
treatments using cost-effectiveness analysis (CEA)
●Therapeutic added value requirements
●These typically involve comparison with other, established drugs in the same class, or with other treatments used
in the standard of care (SoC) with higher prices allowed or negotiated for improved health or health-related effects
in the form of efficacy, better side effect profile, or convenience (a form of internal reference pricing)
●Comparison with the price of the identical product in other countries (‘external reference pricing’)
●This involves setting prices by reference to the prices of the same product in a basket of other countries.
7. Types of price control: five broad types (2)
●Cost-based approaches where manufacturers supply production and research cost information
● Most countries have now moved away from direct price control based on costs and profit margins. The difficulties
of allocating joint costs across global markets and taking account of R&D failures rendered this a particularly
inefficient way of regulating pharmaceutical prices.
●Limits on total spending with various clawback mechanisms to penalize companies individually
or as an industry when revenues exceed the target set
●Controlling expenditure through drug budget caps is a form of ‘silo budgeting,’ which may create perverse
incentives for cost shifting to less efficient inputs or to curb sales of products that are delivering a lot of health
gain.
8. Pricing Proposals in Malaysia1
●Price regulation in public sector procurement but no price regulation or control mechanism in place for sales to the
private sector
●Proposed use of ERP against a group of other countries, then take the three lowest and average the price of these
three
●The ceiling will be imposed at the wholesale and retail / consumer levels (e.g. clinics, hospitals, and pharmacies
●Two phases:
●Phase 1: single source, high value or innovator sourced through public sector procurement
●Phase 2: innovator, biosimilar, and generic medicines in both the public and private sectors
●Recommended Retail prices based on disclosure of R&D costs, manufacturing costs and retail mark-ups
1 This and the next slide is taken from Galen 2019
9. Pricing Proposals in Malaysia part 2
●Price freeze on doctors fees since 1992 means clinics use the mark-up on drugs to continue in
business
●70% of their revenue comes from the sales of medicines
●Community pharmacists operate on low margins and sell many other products. They are cheaper
than hospitals and clinics. Price controls are likely to mean that they are less able to compete
●Hospitals are likely to raise prices on other services in order to recover costs.
●Most public expenditure is on off-patent medicines. It is not clear how price control will impact. If
competition is working then the addition of price control is likely to be ineffective or to lead to
product shortages.
10. Pricing Proposals in Malaysia part 3
●I would argue competition is better than price control.
● where there is no competition, then use of HTA to assess value is a better route than using
price control based on either an (arbitrary) assessment of costs or the use of external reference
pricing
●High clinic and hospital mark ups are better dealt with through competition
●Separate prescribing from dispensing and let patients get drugs from any pharmacy outlet
●Let clinics charge realistic rates for core services so they don’t need to cross- subsidise
●Ensure competition between clinics and between hospitals for patients
●Publish wholesale list prices so patients paying OOP can compare mark ups
11. The challenges of external reference pricing
●It undermines price differentiation across countries
●Price differentiation is the most efficient way to recover R&D costs for innovative products
●If it is used, then the impact on innovation and access will be reduced if countries with similar
GDP per capita, population epidemiology, and health care systems are referenced
●Even so, referencing effectively exports value assessment.
●Implicitly or explicitly the country is saying “we think these countries are paying the right
amount for their drugs”
●Or is the argument “we just want to pay less” ?
12. Is ERP optimally implemented: The 14 principles framework
An analytical framework studying whether national ERP systems adhere to best practice comprising 14
principles (Sullivan, Kanavos & Kalo, 2015) and endeavouring to showcase the performance of national
ERP systems based on these principles
No. ERP best practice principle framework
1 The objectives of ERP systems should be clear and align with health system objectives
2
ERP systems should focus on in-patent products considered for the purposes of coverage, pricing and reimbursement
decisions
3 Prices developed via ERP do not over-ride HTA conclusions or VBP approaches
4 The ERP system should have administrative simplicity and transparency
5 Stakeholders should participate in design and review of ERP system
6 Stakeholders are able to appeal regulator decisions
7 Reference countries should be selected based on similarities in economic status and health system objectives
8 International implications of ERP implementation should be considered
9 Publicly available ex-factory prices should form the basis of the ERP system
10 The mean of prices in reference countries should be used
11 ERP system respects patent status of products it covers based on provision of IP that prevail in reference country
12 ERP formula should avoid the impact of exchange rate volatility
13
Price revisions should be kept to a minimum and should be carried out consistently to avoid the perception of opportunistic
behaviour
14 ERP-based prices should be aligned with other tools used when negotiating reimbursement
Source: Panos Kanavos, LSE
13. Is ERP optimally implemented: The 14 principles framework
An analytical framework studying whether national ERP systems adhere to best practice comprising 14
principles (Sullivan, Kanavos & Kalo, 2015) and endeavouring to showcase the performance of national
ERP systems based on these principles
No. ERP best practice principle framework
1 The objectives of ERP systems should be clear and align with health system objectives
2
ERP systems should focus on in-patent products considered for the purposes of coverage, pricing and reimbursement
decisions
3 Prices developed via ERP do not over-ride HTA conclusions or VBP approaches
4 The ERP system should have administrative simplicity and transparency
5 Stakeholders should participate in design and review of ERP system
6 Stakeholders are able to appeal regulator decisions
7 Reference countries should be selected based on similarities in economic status and health system objectives
8 International implications of ERP implementation should be considered
9 Publicly available ex-factory prices should form the basis of the ERP system
10 The mean of prices in reference countries should be used
11 ERP system respects patent status of products it covers based on provision of IP that prevail in reference country
12 ERP formula should avoid the impact of exchange rate volatility
13
Price revisions should be kept to a minimum and should be carried out consistently to avoid the perception of opportunistic
behaviour
14 ERP-based prices should be aligned with other tools used when negotiating reimbursement
Source: Panos Kanavos, LSE
14. Value-Based Differential Pricing: Setting Optimal Prices for Drugs Cross-
Nationally
●Optimal price levels and differences across markets can be
achieved if each payer unilaterally sets an incremental cost
effectiveness threshold based on its citizens’ willingness to pay
for health and health related gain1
●Manufacturers will price to that ICER
●Payers should limit reimbursement to patients for whom a drug
is cost-effective at that price
●If there are price differentials between patient subgroups
matching value differences, prices will achieve first best static &
dynamic efficiency.
●The resulting price levels and use within each country and price
differentials across countries should be appropriate for second
best static and dynamic efficiency.
Danzon, P., Towse, A. and Mulcahy, A. (2011) Health Affairs. 30(8), 1529-1538.
Danzon, P.; Towse, A.; Mestre-Ferrandiz, J. (2015). Health Economics: 24 (3)
294-301
1For a Malaysian estimate see Lim 2017
15. HTA in Malaysia1
●Drug prices in public facilities are indirectly controlled through guidelines and
directives of the public procurement process.
●The Pharmaceutical Services Program (PSP) carries out an HTA but cost-
effectiveness is not a formal decision criterion for MOH formulary decisions.
Instead, budget impact is used as a criterion. Information and evidence from
this HTA are referred to during price negotiations of drugs for listing. There is
no automatic funding provision for a positive listing.
●Need to develop approaches to assessing value for money. Economic
evidence is currently not mandatory and hence not commonly submitted.
Need to take a view on:
●What local evidence it is realistic to develop (e.g. EQ5D-5L tariff, and local
trial or RWE evidence)
●A realistic timetable to develop skills (on all parties) and build on work of
MaHTAS and PSP to date
1. This slide (including Table 2) is based on Shafie et al. (2019)
17. 15 Principles of HTA: Emphasis on process
Drummond MF, Schwartz JS, Jonsson B, Luce BR, Neumann, PJ, Siebert U, Sullivan SD. Key principles for the conduct of HTA for resource allocation decisions.
International Journal of Technology Assessment in Health Care, 24:3 (2008), 244–258
1. Goal and Scope Explicit and Relevant to Use
2. Unbiased and Transparent Exercise
3. Include All Relevant Technologies
4. Clear System for Setting Priorities Should Exist
5. Incorporate Appropriate Methods for Assessing Costs
and Benefits
6. Consider a Wide Range of Evidence and Outcomes
7. Consider Full Societal Perspective
8. Explicitly Characterize Uncertainty Surrounding
Estimates
9. Consider and Address Issues of Generalizability and
Transferability
10. Actively Engage All Key Stakeholder Groups
11. Actively Seek All Available Data
12. Monitor the Implementation of HTA Findings
13. HTA Should be Timely
14. Appropriately Communicate HTA Findings to
Different Decision Makers
15. Be Transparent and Clearly Define Link Between
HTA Findings and Decision-Making Processes
18. Conclusions
●Some form of price regulation is needed to support UHC
●Rationale for price control in OOP and off-patent markets is less clear
●External Reference Pricing undermines differential pricing and exports pricing policy
●Malaysia has experience and capability in HTA
●Makes sense to develop this to move to value-based pricing for drugs available in the
public sector or reimbursed from public funds
●Moving towards national reimbursement supported by health financing in the long run
19. References (i)
●Danzon, P.; Towse, A.; Mestre-Ferrandiz, J. (2015) Value-based differential pricing: efficient prices for drugs in a global
context. Health Economics Volume: 24 (3) pp. 294-301
●Danzon, P., Towse, A. and Mulcahy, A. (2011) Health Affairs. 30(8), 1529-1538
●Danzon P. (2018) Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues. PharmacoEconomics
https://doi.org/10.1007/s40273-018-0696-4
●Danzon, P. and Towse, A. (2003) Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. Journal of
Health Care Financing and Economics. 3(3), 183-205.
●Drummond MF, Schwartz JS, Jonsson B, Luce BR, Neumann, PJ, Siebert U, Sullivan SD. Key principles for the conduct of
HTA for resource allocation decisions. International Journal of Technology Assessment in Health Care, 24:3 (2008), 244–258
●Galen Centre for Health & Social Policy (2019). Drug Price Controls In Malaysia: Implications and Considerations. Policy Brief
No. 5, June 2019
●Garrison et al. (2012) Health technology assessment in low‐ and middle‐income countries: Findings from a survey and case
studies. Management Sciences for Health.
20. References (ii)
● Hernandez-Villafuerte, K., Garau, M., Towse, A., Garrison, L. and Grewal, S. Policy Options for Formulary Development in Middle-income
Countries. OHE Consulting Report, January 2017
● Hernandez-Villafuerte, K., Garau, M., Towse, A. and Garrison, L. Policy Options for Formulary Development in Middle-income Countries:
Mexico Case Study. OHE Consulting Report, January 2017
● La Mola, F & Sasidharan (2019), A. What Drug Price Controls in Malaysia Mean for the Pharmaceutical Industry. Executive Insights.
Volume XXI, Issue 32. L.E.K. Consulting
● Lim YW et al (2017). Determination of Cost-Effectiveness Threshold for HealthCare Interventions in Malaysia. Value in Health 20: 1131 –
1138
● Shafie, Asrul Akmal et al. (2019) Health Technology Assessment and Its Use in Drug Policy in Malaysia. Value in Health Regional Issues,
Volume 18, 145 - 150
● Towse A. (2014) Value of Drugs in Practice. In: Anthony J. Culyer (ed.), Encyclopedia of Health Economics, Vol 3. : Elsevier; 2014. pp.
432-440
● Towse, A., Devlin, N., Hawe, E. and Garrison, L. (2011) The evolution of HTA in emerging markets health care systems: Analysis to
support a policy response. OHE Consulting Report. London: Office of Health Economics.
21. To keep up with the latest news and research, subscribe to our blog.
OHE’s publications may be downloaded free of charge from our website.
ohe.or
g
OHE
Southside
105 Victoria Street
London SW1E 6QT
United Kingdom
Telephone
+44 (0)20 77478850
FOLLOW US
Toenquire about additional information and analyses,
please contact:
Adrian Towse
atowse@ohe.org